0
Corvus Pharmaceuticals, Inc. Banner Image

Corvus Pharmaceuticals, Inc.

  • Ticker CRVS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Corvus Pharmaceuticals, Inc. Logo Image
  • 51-200 Employees
  • Based in Burlingame, California
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidates are ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, and CPI-006, a humanized monoclonal antibody directed against CD73 that exhibits immunomodulatory activity and activation of immune cells. These product candidates are being studied in ongoing Phase 1b/2 and PhaseMore 1/1b clinical trials in patients with a wide range of advanced solid tumors. Ciforadenant is being evaluated in a successive expansion cohort Phase 1b/2 trial examining its activity both as a single agent and in combination with an anti-PD-L1 antibody. CPI-006 is being evaluated in a multicenter Phase 1/1b clinical trial as a single agent, in combination with ciforadenant and pembrolizumab. The Company’s third cancer clinical program, CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. The Company is also evaluating CPI-006 as a treatment for COVID-19 patients.
Corvus Pharmaceuticals, Inc.

Most Recent Annual Report

Corvus Pharmaceuticals, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Older/Archived Annual Reports